Bayer AG (BAYGn.DE)
* Bayer forms collaboration with academic and governmental institutions for global phase III study to evaluate Xarelto
BUDAPEST, Jan 27 - Hungarian drugmaker Richter expects a contraceptive patch licensed from Bayer HealthCare to produce annual revenues worth 40-50 million euros in three to four years, Chief Executive Erik Bogsch told Reuters on Tuesday.
* Bayer news release: Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source Source text for Eikon: Further company coverage:
* Says bayer receives recommendation for approval for new treatment option with aflibercept solution for injection in eu for the treatment of patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO) Further company coverage:
* Reported on Tuesday that it has signed a contract with Bayer 04 Leverkusen for definitive sale of rights to the player Tin Jedvaj
* Says fda approves bayer's gadavist (gadobutrol) injection as first magnetic resonance contrast agent for pediatric patients less than 2 years of age Further company coverage: (Reporting By Thomas Atkins)
LONDON/HONG KONG - Bankers responsible for floating companies and selling new shares into the market will enjoy a well-earned rest this Christmas after their busiest year since 2007, having notched up business worth almost $865 billion in the last 12 months.
(Adds comments from Bayer's director of U.S. soybean operations)
CHICAGO - China has officially approved imports of a genetically modified Bayer CropScience soybean variety after seven years of review, the company said on Friday, raising expectations that approval notices will come soon for other grains.
CHICAGO, Dec 19 - China has officially approved imports of a genetically modified soybean variety developed by Bayer CropScience after seven years of review, the company said on Friday.
Earnings vs. Estimates
Analyst Research Reports
Validea Guru Analysis Report for BAYRY. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Bayer - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
Bayer AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.